Wolverine (BPC-157 + TB-500)
A recovery-focused research blend pairing BPC-157 with TB-500, marketed for soft-tissue and injury repair. Both components have only animal-level evidence, and there are no human trials of the combination.
In plain English
Nicknamed 'Wolverine' after the comic-book healing factor, this blend combines two of the most popular recovery research peptides: BPC-157 and TB-500. The pitch is faster healing of tendons, ligaments, muscle, and gut tissue. The reality: both peptides are studied almost entirely in rodents, neither has published human randomized trials, neither is FDA-approved, and TB-500 is explicitly banned by WADA. There are no studies of the two used together. Treat it as an experimental combination built on animal data.
What it is
A combination of two research peptides: BPC-157, a synthetic pentadecapeptide derived from a gastric protein, and TB-500, a synthetic fragment related to thymosin beta-4. Sold together as an injury/recovery 'healing stack.' Neither is an approved drug.
Mechanism (summary)
In animal models the components act through complementary repair pathways: BPC-157 is associated with angiogenesis, growth-factor signaling, and tendon/gut healing, while thymosin beta-4 / TB-500 modulates actin and cell migration relevant to wound closure and cardiac repair. The combination is intended to cover both blood-vessel formation and cell-migration aspects of healing, but this synergy is theoretical and untested in controlled studies.
Why people research it
- Tendon, ligament, and muscle injury recovery
- Soft-tissue and post-surgical healing
- Gut and connective-tissue repair
- General 'recovery stack' use in sport and bodybuilding
Human evidence
There are no published human trials of the BPC-157 + TB-500 combination, and none of either component individually in well-powered human RCTs. The human-facing claims rest entirely on rodent studies and anecdote. The FDA flagged BPC-157 in its compounding guidance, and TB-500 is prohibited by WADA. This blend should be considered experimental and unproven in humans.
Animal / lab evidence
Both components have substantial rodent literatures individually: BPC-157 is reported to accelerate Achilles tendon, ligament, and gut-injury healing in rats, and thymosin beta-4 / TB-500 promotes wound healing, endothelial cell migration, and cardiac repair in animal models. There is no controlled animal study of this specific commercial combination; benefits of the pairing are inferred from the separate datasets.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
Supports only the BPC-157 component, and only in animals. It does not test the stack or any human outcome.
Rat-tendon evidence for the BPC-157 half. Encouraging in animals, but not proof for humans or for the combination.
Supports the TB-500 side of the stack via animal repair data. It does not test the combination in people.
History
BPC-157 (isolated from gastric juice, Zagreb, 1990s) and TB-500 (a thymosin beta-4 fragment) became the two most-discussed recovery peptides in athletic and biohacking circles. Vendors bundled them as 'Wolverine,' branding the stack around rapid healing despite the absence of human or combination evidence.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A 15-amino-acid fragment derived from a stomach-protecting protein, widely studied in rodents for gut, tendon, and ligament repair.
A synthetic fragment of thymosin beta-4 studied in animals for wound healing, cardiac repair, and tissue regeneration.
The C-terminal tripeptide of α-MSH studied for anti-inflammatory effects in gut and skin disease.
A naturally occurring copper-binding tripeptide widely used in cosmetics and studied for skin remodeling and wound healing.